BJH - volume 8, issue 2, march 2017
M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)
The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
(BELG J HEMATOL 2017;8(2):53–65)
Read moreBJH - volume 6, issue 2, may 2015
J. Van Droogenbroeck MD, PhD
More than ten years ago the dipeptidyl boronic acid derivative proteasome inhibitor bortezomib changed the therapeutic field of multiple myeloma dramatically. This introduction of a whole new class of chemotherapy lead to a significant extension of disease-free and overall survival for most myeloma patients. But as with most first-in-class molecules, efficacy can probably be improved — primary and secondary bortezomib resistance being common – and treatment is all too often limited by dose-limiting side effects.2 Carfilzomib is without doubt a very promising next generation proteasome inhibitor.
(BELG J HEMATOL 2015;6(2):71–3)
Read moreBJH - volume 5, issue 4, december 2014
M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, KL. Wu MD, PhD, C. Doyen MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).
(BELG J HEMATOL 2014;5(4):125–36)
Read moreBJH - volume 5, issue 4, december 2014
B. Depreter PharmD, E. Dumoulin PharmD, J. Billiet MD, B. Cauwelier MD, PhD, B. Maes MD, PhD, C. Matthys MD, J. Van Droogenbroeck MD, PhD, F. Nollet PhD, J. Emmerechts MD, PhD
We report a rare case of biclonal biphenotypic B-cell lymphocytosis with chronic lymphocytic leukaemia phenotype. Clonality was initially misjudged by immunophenotyping because of its polyphenotypic pattern. Polymerase chain reaction analysis revealed clonality of the immunoglobulin heavy chain and kappa light chain gene rearrangement, indicating the presence of a monoclonal B-lymphocyte population. Immunophenotyping was repeated after cell sorting and revealed two CD5+CD19+ populations with different light chain restriction. Different genetic abnormalities for both clones, as evidenced by fluorescence in situ hybridisation and hypermutation analysis, support the diagnosis of two independently originated but co-existing B-cell clones. This case illustrates the importance of using multiple techniques in the diagnostic work-up of haematological malignancies.
(BELG J HEMATOL 2014;5(4):143–7)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
F. Nollet PhD, K. Boon , J. Emmerechts MD, PhD, S. Vermeire , R. D’Hondt , A. Van Hoof MD, PhD, D. Selleslag MD, J. Van Droogenbroeck MD, PhD, T. Lodewyck MD, J. Billiet MD
BJH - volume 3, issue 4, december 2012
S. Drieghe PharmD, B. Cauwelier MD, PhD, T. Lodewyck MD, D. Selleslag MD, J. Van Droogenbroeck MD, PhD, A. Van Hoof MD, PhD, J. Van Huysse MD, J. Billiet MD
Intravascular lymphoma is a rare haematological malignancy characterised by neoplastic proliferation of lymphoid cells particularly within the lumina of capillaries, heterogeneity in clinical presentation, disseminated disease with aggressive behaviour and often fatal course. In the present case report, we describe four cases of intravascular lymphoma diagnosed in a single centre over a period of ten years.
(BELG J HEMATOL 2012;3: 149–154)
Read more
Top
